Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4937 Target Snapshot

Casein kinase I isoform epsilon · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,442Compounds
336Assays
10Approved Drugs
2,208.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Casein kinase I isoform epsilon shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49674. Start with follicular lymphoma, then reuse UniProt P49674 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with follicular lymphoma, then reuse UniProt P49674 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
follicular lymphoma

Casein kinase I isoform epsilon shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with follicular lymphoma because it currently carries approved-linked support. Linked drugs include UMBRALISIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Casein kinase I isoform epsilon as ChEMBL target CHEMBL4937, mapped to UniProt P49674. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Casein kinase I isoform epsilon
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4937
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49674
Casein kinase I isoform epsilon
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Casein kinase I isoform epsilon is the right protein anchor across sources, using UniProt P49674 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why follicular lymphoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCasein kinase I isoform epsilon
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP49674
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCasein kinase I isoform epsilon
UniProt AccessionP49674
Component TypeProtein
Sequence Length416 aa

Casein kinase I isoform epsilon

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Casein kinase I isoform epsilon, mapped to UniProt P49674. Sequence length is 416 aa.

Mapped IDP49674
Review nameCasein kinase I isoform epsilon
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Casein kinase I isoform epsilon shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
follicular lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Approved-linked Approved
marginal zone B-cell lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Late clinical Phase III
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Clinical signal Phase II
diffuse large B-cell lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Clinical signal Phase II
lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Clinical signal Phase I
esophageal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugUMBRALISIB TOSYLATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with follicular lymphoma because it currently carries approved-linked support. Linked drugs include UMBRALISIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasefollicular lymphoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

10
Approved
4
Phase III
16
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC501,796.0
KI6.0
EC507.0
KD399.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5914602 10.02 IC50 0.095 Preclinical
CHEMBL5948403 10.02 IC50 0.096 Preclinical
CHEMBL5757040 9.89 IC50 0.128 Preclinical
CHEMBL5819750 9.77 IC50 0.17 Preclinical
CHEMBL6017462 9.74 IC50 0.183 Preclinical
CHEMBL5885676 9.74 IC50 0.182 Preclinical
CHEMBL3962177 9.7 IC50 0.2 Preclinical
CHEMBL5884113 9.65 IC50 0.222 Preclinical
CHEMBL5742519 9.65 IC50 0.225 Preclinical
CHEMBL5883463 9.63 IC50 0.233 Preclinical
Distribution

pChEMBL Value Distribution

38
5.0
122
5.5
96
6.0
113
6.5
184
7.0
210
7.5
234
8.0
174
8.5
52
9.0
15
9.5
pChEMBL
Approved Drugs

Approved Drugs

NERATINIB
CHEMBL180022
Approved 2017
Properties Compare Identifier
NINTEDANIB
CHEMBL502835
Approved 2014
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
SUNITINIB
CHEMBL535
Approved 2006
Properties Compare Identifier
ERLOTINIB
CHEMBL553
Approved 2004
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
Assay Landscape

Assay Landscape

336
Total Assays
1,173
Tested Compounds
3
Assay Types
Binding — 332 assays, 1,173 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 235 1,058 7.6
assay format 48 12 6.6
cell-based format 33 86 6.3
subcellular format 16 17 5.8
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1 6.2
ADME — 2 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —
cell-based format 1 7 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine